CancerDrs

Cervical Cancer clinical trials in Pennsylvania

55 actively recruiting cervical cancer trials at 56 sites across Pennsylvania.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061977
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Saint Luke's Cancer Center - Allentown — Allentown, Pennsylvania
  • Saint Luke's University Hospital-Bethlehem Campus — Bethlehem, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Pocono Medical Center — East Stroudsburg, Pennsylvania
  • Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Pennsylvania:
  • Carlisle Regional Cancer Center — Carlisle, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus — Harrisburg, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in Pennsylvania:
  • Site 43 — Philadelphia, Pennsylvania
  • Site 153 — Philadelphia, Pennsylvania
  • Site 154 — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Pennsylvania:
  • Fox Chase Cancer Center — Philadelphia, Pennsylvania
  • University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progres…

Sponsor: AstraZeneca
NCT ID: NCT06079671
Sites in Pennsylvania:
  • Research Site — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • UPMC Altoona — Altoona, Pennsylvania
  • UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
  • Lehigh Valley Hospital - Muhlenberg — Bethlehem, Pennsylvania
  • Carlisle Regional Cancer Center — Carlisle, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Pennsylvania:
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
  • Jefferson Torresdale Hospital — Philadelphia, Pennsylvania
  • Asplundh Cancer Pavilion — Willow Grove, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Pennsylvania:
  • UPMC Altoona — Altoona, Pennsylvania
  • Geisinger Medical Center — Danville, Pennsylvania
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
  • IRMC Cancer Center — Indiana, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Pennsylvania:
  • Chambersburg Hospital — Chambersburg, Pennsylvania
  • Ephrata Cancer Center — Ephrata, Pennsylvania
  • UPMC Hillman Cancer Center Erie — Erie, Pennsylvania
  • UPMC Cancer Center at UPMC Horizon — Farrell, Pennsylvania
  • Adams Cancer Center — Gettysburg, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-postive salivary gland cancer that has come back (recurrent), that has spread from where …

Sponsor: NRG Oncology
NCT ID: NCT05408845
Sites in Pennsylvania:
  • UPMC Altoona — Altoona, Pennsylvania
  • UPMC-Heritage Valley Health System Beaver — Beaver, Pennsylvania
  • UPMC Hillman Cancer Center at Butler Health System — Butler, Pennsylvania
  • UPMC Camp Hill — Camp Hill, Pennsylvania
  • Carlisle Regional Cancer Center — Carlisle, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Pennsylvania:
  • Lehigh Valley Hospital-Cedar Crest — Allentown, Pennsylvania
  • Penn State Children's Hospital — Hershey, Pennsylvania
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
  • Children's Hospital of Pittsburgh of UPMC — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Pennsylvania:
  • Cancer Care Associates of York (site 206) — York, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Pennsylvania:
  • University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.

Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06123338
Sites in Pennsylvania:
  • University of Pennsylvania (Data Collection Only) — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…

Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Pennsylvania:
  • Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Pennsylvania:
  • University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN…

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05977907
Sites in Pennsylvania:
  • Thomas Jefferson University Hospital — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …

Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06458036
Sites in Pennsylvania:
  • Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

This is a single institution, multi-center, Phase II, single-arm study, using Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT) in the post-surgical, adjuvant setting for definitive treatment of gynecologic cancers. The pur…

Sponsor: Abramson Cancer Center at Penn Medicine
NCT ID: NCT05758688
Sites in Pennsylvania:
  • Lancaster General Health - Ann B. Barshinger Cancer Institute — Lancaster, Pennsylvania
  • University of Pennsylvania — Philadelphia, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or met…

Sponsor: CJ Bioscience, Inc.
NCT ID: NCT05877430
Sites in Pennsylvania:
  • University of Pittsburgh — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

Researchers are looking for new ways to treat esophageal squamous cell carcinoma (ESCC). ESCC is a type of cancer that starts in certain cells that line the esophagus. The esophagus is the tube that connects the throat to the stomach. This…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780111
Sites in Pennsylvania:
  • UPMC Hillman Cancer Center ( Site 1904) — Pittsburgh, Pennsylvania
View on ClinicalTrials.gov →

Showing 25 of 55 trials with sites in Pennsylvania. See all cervical cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07